Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become
an important cell source to address the lack of primary cardiomyocytes available for basic
research and translational applications. To differentiate hiPSCs into cardiomyocytes, various
protocols including embryoid body (EB)-based differentiation and growth factor induction
have been developed. However, these protocols are inefficient and highly variable in their
ability to generate purified cardiomyocytes. Recently, a small molecule-based protocol …